These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 30404653)

  • 21. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.
    Douillard-Guilloux G; Raben N; Takikita S; Ferry A; Vignaud A; Guillet-Deniau I; Favier M; Thurberg BL; Roach PJ; Caillaud C; Richard E
    Hum Mol Genet; 2010 Feb; 19(4):684-96. PubMed ID: 19959526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.
    Khanna R; Powe AC; Lun Y; Soska R; Feng J; Dhulipala R; Frascella M; Garcia A; Pellegrino LJ; Xu S; Brignol N; Toth MJ; Do HV; Lockhart DJ; Wustman BA; Valenzano KJ
    PLoS One; 2014; 9(7):e102092. PubMed ID: 25036864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.
    Rucker M; Fraites TJ; Porvasnik SL; Lewis MA; Zolotukhin I; Cloutier DA; Byrne BJ
    Development; 2004 Jun; 131(12):3007-19. PubMed ID: 15169761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
    Ziegler RJ; Bercury SD; Fidler J; Zhao MA; Foley J; Taksir TV; Ryan S; Hodges BL; Scheule RK; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2008 Jun; 19(6):609-21. PubMed ID: 18500944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycogen accumulation in smooth muscle of a Pompe disease mouse model.
    McCall AL; Dhindsa JS; Bailey AM; Pucci LA; Strickland LM; ElMallah MK
    J Smooth Muscle Res; 2021; 57(0):8-18. PubMed ID: 33883348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term, high-level hepatic secretion of acid α-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus.
    Rastall DP; Seregin SS; Aldhamen YA; Kaiser LM; Mullins C; Liou A; Ing F; Pereria-Hicks C; Godbehere-Roosa S; Palmer D; Ng P; Amalfitano A
    Gene Ther; 2016 Oct; 23(10):743-752. PubMed ID: 27367841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.
    Todd AG; McElroy JA; Grange RW; Fuller DD; Walter GA; Byrne BJ; Falk DJ
    Ann Neurol; 2015 Aug; 78(2):222-34. PubMed ID: 25925726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autophagy in skeletal muscle: implications for Pompe disease.
    Shea L; Raben N
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa
    Sellier P; Vidal P; Bertin B; Gicquel E; Bertil-Froidevaux E; Georger C; van Wittenberghe L; Miranda A; Daniele N; Richard I; Gross DA; Mingozzi F; Collaud F; Ronzitti G
    J Inherit Metab Dis; 2024 Jan; 47(1):119-134. PubMed ID: 37204237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism.
    Canibano-Fraile R; Harlaar L; Dos Santos CA; Hoogeveen-Westerveld M; Demmers JAA; Snijders T; Lijnzaad P; Verdijk RM; van der Beek NAME; van Doorn PA; van der Ploeg AT; Brusse E; Pijnappel WWMP; Schaaf GJ
    J Inherit Metab Dis; 2023 Jan; 46(1):101-115. PubMed ID: 36111639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
    Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH
    Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genotype-phenotype correlation in Pompe disease.
    Kroos M; Hoogeveen-Westerveld M; van der Ploeg A; Reuser AJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):59-68. PubMed ID: 22253258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
    Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
    J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy.
    Raben N; Lu N; Nagaraju K; Rivera Y; Lee A; Yan B; Byrne B; Meikle PJ; Umapathysivam K; Hopwood JJ; Plotz PH
    Hum Mol Genet; 2001 Sep; 10(19):2039-47. PubMed ID: 11590121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
    Douillard-Guilloux G; Richard E; Batista L; Caillaud C
    J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neural deficits contribute to respiratory insufficiency in Pompe disease.
    DeRuisseau LR; Fuller DD; Qiu K; DeRuisseau KC; Donnelly WH; Mah C; Reier PJ; Byrne BJ
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9419-24. PubMed ID: 19474295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.